Peer-Reviewed Publication
JAMA Neurol2026;83(2):126-136.February 1, 2026Journal Article

Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch.

Christopher A Brown1, Nidhi S Mundada2, Katheryn A Q Cousins1, Niyousha Sadeghpour3, Xueying Lyu2, Emily McGrew1, Magdalena Korecka4, Alice Chen-Plotkin1,4, Long Xie5, Laura E M Wisse6, John A Detre1,3, Corey T McMillan1, Edward B Lee4, Ilya M Nasrallah3, Sandhitsu R Das1, Dawn Mechanic-Hamilton1, Paul A Yushkevich3, Leslie M Shaw4, David A Wolk1,
1Department of Neurology, University of Pennsylvania, Philadelphia.
2Department of Bioengineering, University of Pennsylvania, Philadelphia.
3Department of Radiology, University of Pennsylvania, Philadelphia.
4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.
5Department of Digital Technology and Innovation, Siemens Healthineers, Princeton, New Jersey.
6Department of Clinical Sciences, Lund University, Lund, Sweden.

Abstract

IMPORTANCE: Even within individuals who are amyloid positive, clinical symptoms can be impacted by Alzheimer pathology, other pathologic proteins, and cognitive reserve or resilience. Understanding how each of these factors contributes to a patient's clinical presentation is crucial for prognosis and treatment decisions in the era of disease-modifying therapies. OBJECTIVE: To evaluate tau-clinica…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.